Skip To The Main Content

PDA EU00018 CMC Regulatory Compliance for Biopharmaceuticals

Sep 16 - Sep 17, 2021
Berlin, Germany

  • Education
  • Europe

left to register

Note   COVID-19 situation up-date 30th March 2020:

PDA is closely monitoring the Corona virus situation. 

Should an event need to be postponed or cancelled, PDA will send email updates to all participants with additional details and information.

If you have any immediate questions or requests, please contact [email protected]. Additionally, you may visit the PDA official statement on our website.


Biopharmaceuticals are being developed by many companies whose Chemistry, Manufacturing & Control (CMC) teams have varying degrees of familiarity or experience with the regulatory requirements for these challenging products. Companies clearly understand the critical importance of their human clinical study strategy, but frequently, the development of a strategy for Chemistry, Manufacturing & Controls (CMC) is an afterthought. Add the frequent lack of CMC regulatory compliance experience in some companies, coupled with the complexity of the biological manufacturing processes and products, and this can be a recipe for disaster.

This course will provide insights and practical guidance for the CMC teams to develop an acceptable cost-effective CMC regulatory compliance strategy for biopharmaceuticals from early clinical stage development through market approval. The course emphasis will include FDA, EMA and ICH guidance.


  • Day 1
  • Day 2
  • 9:00
    Welcome and Introduction

    CMC Regulatory Challenges for Biopharmaceuticals are Different

    Painting the Terminology Landscape: Biologic, specified biologic, biopharmaceutical, biosimilar, CBER, CDER, EMA, ...

    Coffee Break


    Understanding the CMC Differences of Biopharmaceutical Regulation between FDA and EMA

    Biopharmaceuticals are not Chemical Drugs – Regulatory Compliance Consequences of the four Major CMC Differences

    Lunch Break

    How to Develop an Effective Corporate CMC Risk-Managed Control Strategy for Biopharmaceuticals


    Three Major Forces that Shape the CMC Regulatory Compliance Strategy of all Biopharmaceuticals/li>

    Five Key Elements of an Effective Corporate CMC Regulatory Compliant Strategy

    Coffee Break


    Impact of the Quality by Design (QbD) on Biopharmaceutical CMC Strategy

    Necessity of a Clinical Phase - Appropriate CMC Regulatory Compliance Strategy

    End of Day 1

  • Applying a CMC Risk-Managed Control Strategy to the Biopharmaceutical Manufacturing Process


    Four Myths about Biopharmaceutical Starting Material – the Master Cell Bank

    Necessity of Confirming Clonality and Genetic Stability

    Coffee Break


    Importance and Limitations of small-scale Studies for Biopharmaceuticals

    Clinical Phase - Appropriate Control of the Biopharmaceutical Manufacturing Process

    Formulation and Container-Closure Challenges for Biopharmaceuticals – Impact of Components on the Biopharmaceutical (e.g., protein aggregation) and Impact of the Biopharmaceutical on Components (e.g., glass delamination)

    Lunch Break

    Challenge of Managing Manufacturing Process Changes and Demonstrating Biologic Product Comparability – Not an Easy Task!


    Need for Risk-based, Sequential and Clinical Phase - Appropriate Comparability Studies

    Demonstrating Biologic Product Comparability – Justifying CMC Differences

    Coffee Break


    “Comparability Protocol” and “Post Approval Change Management Protocol”

    Extreme Comparability of Biosimilars: Limitations of CMC Comparison, Fingerprinting – CMC Biosimilarity Successes and Failures

    End of Training Course


John Geigert
John Geigert
Biopharmaceutical Quality Solutions

Additional Information

  • Learning Objectives

    Learning Objectives

    Upon completion of this course, you will be able to:

    • Explain the importance and underlying principles of an effective CMC regulatory strategy for biopharmaceuticals to move your products through clinical development into the marketplace
    • Explain the importance and underlying principles for CMC regulatory compliance of biopharmaceuticals and how this leads regulatory agencies to have different CMC regulatory requirements for biotech products compared to pharmaceuticals of chemical origin.
  • Who Should Attend

    Who Should Attend

    This course is designed specifically for those involved in or interested in the manufacture and control and CMC regulatory compliance issues of biopharmaceuticals, including Senior Management, Directors and Managers/Supervisors, QA, QC, Regulatory Affairs, Manufacturing and Process Development personnel.

Got a Question? We have answers

Contact Us


PLEASE READ  PDA is not affiliated or contracted with any outside hotel contracting company. If someone other than PDA or the PDA chosen hotel contacts you suggesting that they represent any PDA event, they do not. It is PDA's recommendation that you book your hotel directly through the official PDA chosen hotel that is listed on our web site.

Berlin, Germany

How to Get Here

By Air

More information coming soon.

By Car

More information coming soon.

Other Options

More information coming soon.


Registration Fees

Regular Price
Registration Type All Participants
€ 1595

All fees given in Euro and excluding VAT

* For this member type or discount, online registration is not available, please contact [email protected].

Group Registration Discount: Register 3 people from the same organization as a group (at the same time) for the event and receive the 4th registration free. Other discounts cannot be applied.

GENERAL TERMS AND CONDITIONS: PDA will send you a confirmation letter within one week of payment being received. You must have this confirmation letter to be considered enrolled in a PDA event. If you have submitted a purchase order or requested an invoice, please be advised that a credit card guarantee is needed. PDA reserves the right to modify the material or speakers/trainers without notice or to cancel an event. If an event is cancelled, registrants will be notified by PDA immediately and will receive a credit (registration fee paid). PDA will not be responsible for any costs incurred by registrants due to cancellation. Please note that the attendee list is shared with attendees, trainers, and exhibitors and may be used to follow up on specific areas of interest after the event. Video, photo, and audio recordings are prohibited at all PDA events.

CANCELLATION: If a cancellation request is received 30 days before the event, a credit (registration fee paid minus a 200.00 USD/EUR processing fee) will be given. No credits will be given for cancellation requests received less than 30 days before the event. Cancellation requests must be emailed to [email protected].


Become a Sponsor

Interested in becoming a sponsor? Learn about opportunities and benefits.

Request Information


Attendee List Email Scam

Unfortunately, emails are circulating that offer to sell attendee lists for many of PDA’s conferences and events. These emails are sent by scammers.

Note: PDA does not sell its exhibitor or attendee lists, and no third-party is authorized to distribute or sell any lists related to our events. Statements claiming to offer our attendee lists are fraudulent. If you receive emails that propose to sell PDA conference attendee lists, do not engage with the sender and delete the message immediately.

Become an Exhibitor

Interested in becoming an exhibitor? Learn about opportunities and benefits.

Request Information

Media Partners


Program Inquiries
Exhibition Inquiries
Training Course Inquiries

Tel: +1 (301) 656-5900
[email protected]

Tel: +49 (0) 30 43 655 08-10

Registration Customer Care

Tel: +1 (301) 656-5900 ext. 115
[email protected]

PDA Members Save Substantially